Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 111; no. 48; pp. 17266 - 17271
• Main Authors: Zhang, Suping, Cui, Bing, Lai, Hsien, Liu, Grace, Ghia, Emanuela M., Widhopf, George F., Zhang, Zhuhong, Wu, Christina C. N., Chen, Liguang, Wu, Rongrong, Schwab, Richard, Carson, Dennis A., Kipps, Thomas J.
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 02.12.2014; National Acad Sciences
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacology; Biological Sciences; Cancer; Cancer therapies; Cell Line, Tumor; Cell lines; Cellular immunity; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterologous transplantation; Humans; Immunoblotting; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Molecular Targeted Therapy - methods; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - prevention & control; Prognosis; Receptor Tyrosine Kinase-like Orphan Receptors - genetics; Receptor Tyrosine Kinase-like Orphan Receptors - immunology; Receptor Tyrosine Kinase-like Orphan Receptors - metabolism; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Rodents; Signatures; Spheroids; Spheroids, Cellular - drug effects; Spheroids, Cellular - metabolism; Stem cells; Transplantation, Heterologous; Tumors; PDX mice model; ovarian cancer stem cell; ROR1; monoclonal antibody

Although initially responsive to chemotherapy, many patients with ovarian cancer subsequently develop relapsed and potentially fatal metastatic disease, which is thought to develop from cancer stem cells (CSCs) that are relatively resistant to conventional therapy. Here, we show that CSCs express a...